Episode 19 – A current look into adoptive cell therapies
Tune into this podcast to hear experts discussing the current landscape of adoptive cell therapies!
List view / Grid view
Tune into this podcast to hear experts discussing the current landscape of adoptive cell therapies!
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organization. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
Drug Target Review connects with Dr Stefan Braam, co-founder and CTO of Cellistic, and Andy Holt, CCO of Cellistic, for a rundown on today’s landscape for allogeneic cell therapies.
The team are the first researchers in the world to successfully create an organoid containing both heart muscle cells and cells of the outer layer of the heart wall.
Tune into this podcast to hear experts discussing scaling up 3D organoids!
The natural process of removing damaged cell parts could present an alternative to antibiotics, especially where bacteria have become resistant to existing drugs.
The researchers found restoring mitochondrial homeostasis in the diseased neurons could protect the optic nerve cells from being damaged from glaucoma.
Tune into this podcast to hear experts discuss imaging and analysing data from organoids!
A novel all-optical system uses optogenetics, machine vision cameras, and off-the-shelf components to stimulate and image engineered networks of human heart cells.
The scientists hope the human body plan will increase the understanding of the aetiology and pathology of disease.
The findings provide insight into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
Scientists generated kidney organoids and used them to identify potential drugs to treat autosomal dominant polycystic kidney disease.
In a pre-clinical study, researchers from the US set out to develop a treatment for sepsis. Here, Daniel Morales-Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, describe how they utilised haematopoietic stem and progenitor cell infusion to improve the survival of mice from sepsis.